{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T16:08:15Z","timestamp":1778947695437,"version":"3.51.4"},"reference-count":32,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,3,1]],"date-time":"2013-03-01T00:00:00Z","timestamp":1362096000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1016\/j.jaad.2012.08.010","type":"journal-article","created":{"date-parts":[[2012,10,5]],"date-time":"2012-10-05T20:45:18Z","timestamp":1349469918000},"page":"404-411","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":81,"title":["Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patients"],"prefix":"10.1016","volume":"68","author":[{"given":"Yael A.","family":"Leshem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmilia","family":"Hodak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"David","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grant J.","family":"Anhalt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Mimouni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2012.08.010_bib1","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1172\/JCI114036","article-title":"Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases","volume":"83","author":"Stanley","year":"1989","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jaad.2012.08.010_bib2","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.ceb.2004.07.006","article-title":"Desmosomes and disease: pemphigus and bullous impetigo","volume":"16","author":"Payne","year":"2004","journal-title":"Curr Opin Cell Biol"},{"key":"10.1016\/j.jaad.2012.08.010_bib3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1016\/0092-8674(91)90360-B","article-title":"Autoantibodies against a novel epithelial cadherin in pemphigus vulgaris, a disease of cell adhesion","volume":"67","author":"Amagai","year":"1991","journal-title":"Cell"},{"key":"10.1016\/j.jaad.2012.08.010_bib4","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0733-8635(05)70010-3","article-title":"The risks of systemic corticosteroid use","volume":"16","author":"Lester","year":"1998","journal-title":"Dermatol Clin"},{"issue":"1","key":"10.1016\/j.jaad.2012.08.010_bib5","first-page":"CD006263","article-title":"Interventions for pemphigus vulgaris and pemphigus foliaceus","author":"Martin","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2012.08.010_bib6","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1038\/jid.2010.91","article-title":"Treating pemphigus vulgaris with prednisone and mycophenolate mofetil: a multicenter, randomized, placebo-controlled trial","volume":"130","author":"Beissert","year":"2010","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2012.08.010_bib7","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1067\/mjd.2002.126273","article-title":"Anti-CD20 chimeric monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder","volume":"47","author":"Salopek","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.08.010_bib8","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa067752","article-title":"A single cycle of rituximab for the treatment of severe pemphigus","volume":"357","author":"Joly","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.08.010_bib9","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1111\/j.1365-2133.2011.10411.x","article-title":"Clinical efficacy of different doses of rituximab in the treatment of pemphigus: a retrospective study of 27 patients","volume":"165","author":"Kim","year":"2011","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.08.010_bib10","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jaad.2010.07.032","article-title":"Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients","volume":"65","author":"Kasperkiewicz","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.08.010_bib11","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/archderm.143.8.1033","article-title":"Treatment of severe pemphigus with rituximab: report of 12 cases and a review of the literature","volume":"143","author":"Cianchini","year":"2007","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2012.08.010_bib12","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1056\/NEJMoa062930","article-title":"Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin","volume":"355","author":"Ahmed","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.08.010_bib13","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/jid.2008.192","article-title":"B-cell-directed therapy for inflammatory skin diseases","volume":"129","author":"Nagel","year":"2009","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.jaad.2012.08.010_bib14","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/art.21617","article-title":"Repopulation of B lymphocytes in peripheral blood following B lymphocyte depletion with rituximab in rheumatoid arthritis","volume":"54","author":"Leandro","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2012.08.010_bib15","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1182\/blood.V90.6.2188","article-title":"IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma","volume":"90","author":"Maloney","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.jaad.2012.08.010_bib16","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.1056\/NEJMoa032534","article-title":"Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis","volume":"350","author":"Edwards","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.08.010_bib17","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2012.08.010_bib18","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.jaad.2012.08.010_bib19","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1093\/rheumatology\/ker253","article-title":"Retreatment with rituximab based on a treatment-to-target approach provides better disease control than treatment as needed in patients with rheumatoid arthritis: a retrospective pooled analysis","volume":"50","author":"Emery","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.jaad.2012.08.010_bib20","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.jaad.2008.01.012","article-title":"Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus","volume":"58","author":"Murrell","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.08.010_bib21","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0190-9622(03)02738-5","article-title":"Differences and similarities among expert opinions on the diagnosis and treatment of pemphigus vulgaris","volume":"49","author":"Mimouni","year":"2003","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2012.08.010_bib22","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJM198205203062001","article-title":"Induction of pemphigus in neonatal mice by passive transfer of IgG from patients with the disease","volume":"306","author":"Anhalt","year":"1982","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2012.08.010_bib23","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/j.1749-6632.2009.04744.x","article-title":"Rituximab in severe pemphigus","volume":"1173","author":"Schmidt","year":"2009","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.jaad.2012.08.010_bib24","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2133.2011.10663.x","article-title":"Low dose rituximab is effective in pemphigus","volume":"166","author":"Horv\u00e1th","year":"2012","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2012.08.010_bib25","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1111\/j.1365-4632.2008.03423.x","article-title":"Two courses of rituximab (anti-CD20 monoclonal antibody) for recalcitrant pemphigus vulgaris","volume":"47","author":"Faurschou","year":"2008","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2012.08.010_bib26","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2230.2005.01941.x","article-title":"Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed","volume":"31","author":"Belgi","year":"2006","journal-title":"Clin Exp Dermatol"},{"key":"10.1016\/j.jaad.2012.08.010_bib27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1159\/000099591","article-title":"Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab)","volume":"214","author":"Marzano","year":"2007","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2012.08.010_bib28","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1001\/archderm.140.1.91","article-title":"Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody)","volume":"140","author":"Dupuy","year":"2004","journal-title":"Arch Dermatol"},{"key":"10.1016\/j.jaad.2012.08.010_bib29","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1111\/j.1610-0387.2007.06602.x","article-title":"Recommendations for the use of rituximab (anti-CD20 antibody) in the treatment of autoimmune bullous skin diseases","volume":"6","author":"Hertl","year":"2008","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1016\/j.jaad.2012.08.010_bib30","article-title":"Efficacy and safety of rituximab treatment in Indian pemphigus patients","author":"Kanwar","year":"2011","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"3","key":"10.1016\/j.jaad.2012.08.010_bib31","first-page":"CD005590","article-title":"Prophylaxis for pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients","author":"Green","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaad.2012.08.010_bib32","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000100876","article-title":"Rituximab (anti-CD20 monoclonal antibody)\u2013ultimate or first choice in pemphigus?","volume":"214","author":"Hertl","year":"2007","journal-title":"Dermatology"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962212008638?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962212008638?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:26:19Z","timestamp":1759271179000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962212008638"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":32,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["S0190962212008638"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2012.08.010","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Successful treatment of pemphigus with biweekly 1-g infusions of rituximab: A retrospective study of 47 patients","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2012.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2012.10.018","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 American Academy of Dermatology, Inc. Published by Mosby, Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}